SEC Form 4 · accession 0001140361-18-014190
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Mar 15, 2018
Accepted (ET)
Mar 19, 2018 · 9:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2018 | F | 4,861 | $83.57 | D | 146,448 | D | |
| Common StockF1 | Mar 15, 2018 | A | 16,040 | $0.00 | A | 162,488 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F2 | $83.57 | Mar 15, 2018 | A | 51,300 | A | Mar 15, 2019 | Mar 14, 2028 | Common Stock | 51,300 | 51,300 | D |
Explanation of responses
- F1Restricted stock units granted on March 15, 2018. Price not applicable.
- F2Option grant vests 12/48th on March 15, 2019 and 1/48th on the 15th day of each month thereafter.